FIDIA SPA (FDA.MI) Forecast, Price Target & Analyst Ratings

BIT:FDA • IT0005654683

0.0611 EUR
+0 (+3.56%)
Last: Mar 4, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for FIDIA SPA (FDA.MI).

Forecast Snapshot

Consensus Price Target

Price Target
N/A
N/A

Next Earnings Forecast

Earnings Estimate
Release DateN/A

ChartMill Buy Consensus

Rating
45.71%
Weighted Analyst Rating Score

Price Target Details & History

Consensus Price Target and Range

Mean target
N/A
Upside
N/A
From current price of €0.06 to mean target of N/A, Based on 7 analyst forecasts
Low
N/A
Median
N/A
High
N/A

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

 → Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

FDA Current Analyst RatingFDA Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0.5 1 1.5 2 2.5

Analyst Ratings History

FDA Historical Analyst RatingsFDA Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
45.71%
FDA.MI was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about FDA.MI.
In the previous month the buy percentage consensus was at a similar level.
FDA.MI was analyzed by 7 analysts. More opinions would make the average more meaningful.
 → Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Next Earnings Forecast Details

Next Earnings Details

Release DateN/A

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

 → Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2022 2023 2024
Revenue
YoY % growth
FDA.MI revenue by date.FDA.MI revenue by date.
24.366M
2.22%		28.606M
17.40%		17.486M
-38.87%
EBITDA
YoY % growth
FDA.MI ebitda by date.FDA.MI ebitda by date.
-2.3M
-632.41%		-164K
92.87%		-4.85M
-2,857.32%
EBIT
YoY % growth
FDA.MI ebit by date.FDA.MI ebit by date.
-4.436M
-195.54%		-1.446M
67.40%		-6.186M
-327.80%
Operating Margin
FDA.MI operating margin by date.FDA.MI operating margin by date.
-18.21%-5.05%-35.38%
EPS
YoY % growth
FDA.MI eps by date.FDA.MI eps by date.
N/AN/AN/A

All data in EUR

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in EUR

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

FDA.MI Yearly Revenue VS EstimatesFDA.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
FDA.MI Yearly EPS VS EstimatesFDA.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 0 50 -50

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
N/A
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

FIDIA SPA / FDA.MI Forecast FAQ

What is the number of analysts for FDA stock?

The number of analysts covering FIDIA SPA (FDA.MI) is 7.